ArticleAmerican journal of translational research2025
Network pharmacology-guided investigation of Fuzheng Yanggan Huaxian decoction in a CCL
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural drugs modulate MAPK: targets and strategies for liver fibrosis treatment.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study employed a carbon tetrachloride (CCl
methodsNetwork pharmacology analysis was conducted to identify the Toll-like receptor 4 (TLR4)-mitogen-activated protein kinase (MAPK)/nuclear factor-kappa B (NF-κB) signaling pathway as a key regulatory axis, which was subsequently validated through in vivo experiments.
resultsFZYGHX treatment preserved liver morphology, reduced serum aspartate aminotransferase and alanine aminotransferase levels, and mitigated histopathological damage. Histological assessments demonstrated improved liver architecture, reduced fibrosis, and suppressed collagen deposition. Mechanistically, FZYGHX attenuated hepatic inflammation by downregulating macrophage marker F4/80 and pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha. Furthermore, FZYGHX reinforced intestinal barrier function by upregulating tight junction (TJ) proteins (zonula occludens-1 (ZO-1), claudin-1, and occludin), while decreasing serum lipopolysaccharide (LPS) and hepatic LPS-binding protein (LBP) levels. The FITC-dextran assay confirmed restoration of mucosal barrier integrity.
conclusionThese findings suggest that the anti-fibrotic effects of FZYGHX are mediated, at least in part, by inhibition of the TLR4-MAPK/NF-κB pathway and enhancement of intestinal barrier function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.